Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001)

Keyphrases

• Anticancer Drugs 8%
• Aqueous Solubility 8%
• Biopharmaceutical Classification System 8%
• Chemotherapeutic Regimens 8%
• Clinical Testing 100%
• Docetaxel 100%
• Dose Accuracy 8%
• Ethanol 8%
• Hard Gelatin Capsules 8%
• Inter-individual Variability 8%
• Low Permeability 8%
• No Significant Difference 8%
• Oral Administration 8%
• Oral Bioavailability 8%
• Oral Chemotherapeutic 8%
• Oral Solids 100%
• Pharmaceutical Development 100%
• Pharmacokinetic Booster 16%
• Pharmacokinetic Parameters 8%
• Phase I Clinical Trial 8%
• Polysorbate 8%
• Polyvinylpyrrolidone K30 8%
• Premixed 33%
• Ritonavir 8%
• Sodium Lauryl Sulfate 8%
• Solid Dispersion 8%
• Solid Dispersion Formulation 100%
• Solid Oral Dosage Forms 8%
• Ternary Mixture 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 8%
• Bioavailability 8%
• Clinical Trial 8%
• Docetaxel 100%
• Dosage Forms 8%
• Epileptic Absence 8%
• Gelatin 8%
• Pharmacokinetic Parameter 8%
• Pharmacokinetics 16%
• Polysorbate 8%
• Povidone 8%
• Ritonavir 8%
• Sodium Dodecyl Sulfate 8%